Navigation Links
Pivotal Data Demonstrating Efficacy of Plenadren® (Hydrocortisone, Modified Release Tablet) in Adrenal Insufficiency Published in the Journal of Clinical Endocrinology and Metabolism
Date:2/16/2012

EXTON, Pa., Feb. 16, 2012 /PRNewswire/ -- ViroPharma Incorporated (NASDAQ: VPHM) today announced that data from the pivotal study for their orphan drug Plenadren® (hydrocortisone, modified release tablet) were published in the Journal of Clinical Endocrinology and Metabolism (JCEM), a leading scientific journal for endocrinology. Plenadren was recently granted European Marketing Authorization for treatment of adrenal insufficiency in adults.

The authors described results showing that the once daily dual-release tablet provided a more circadian-based serum cortisol profile, and that reduced body weight, reduced blood pressure, and improved glucose metabolism were observed during once daily treatment, compared to treatment with immediate release hydrocortisone three times per day.  In particular, the authors noted glucose metabolism improved in patients with concomitant diabetes mellitus. In addition, the preference of once daily versus three times per day treatment was assessed to be large or very large by 85 percent of patients at 12 weeks.

Professor Gudmundur Johannsson of the Department of Endocrinology, Sahlgrenska University Hospital, Gothenburg, Sweden, and primary author of the publication, commented, "These data indicate that patients with Addison's Disease now have an important therapeutic option with once daily Plenadren.  The time-exposure of Plenadren may be important in improving the outcome of patients suffering with adrenal insufficiency." 

Replacement therapy for the treatment of the rare disease adrenal insufficiency has been available for more than 50 years. Oral hydrocortisone is the most widely used replacement therapy for treatment, but no formal studies of its efficacy and safety have been performed in patients suffering from adrenal insufficiency. The JCEM publication entitled, 'Improved Cortisol Exposur
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
4. Genzyme Announces Second Pivotal Mozobil Trial Meets Primary Endpoint
5. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
6. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
7. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
8. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
9. Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunction (OBD)
10. Interim Response and Safety Analyses Support Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma
11. Arbios Provides Clinical Strategy for SEPET(TM) Pivotal Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... China Biologic Products, Inc. (Nasdaq: CBPO, "China Biologic" or ... in China , today announced that ... issued by Shanghai RAAS Blood Products Co., Ltd. ("Shanghai ... that on May 21, 2013, Ms. Siu ... shareholders of the Company, and her spouse, Mr. Tung ...
(Date:5/24/2013)... , May 24, 2013  Auxilium Pharmaceuticals, Inc. (Nasdaq: ... will participate in the Deutsche Bank Health Care Conference ... Waterfront Hotel.  Mr. Adrian Adams , ... an overview of the Company and its product pipeline ...   (Logo: http://photos.prnewswire.com/prnh/20101202/MM10881LOGO ) ...
(Date:5/24/2013)... YORK , May 24, 2013 In accordance ... Rules and Rule 14e-1 of the United States Exchange Act, ... its original offer for Elan Corporation (NYSE: ELN). ... Limited ("Royalty Pharma") made an offer for the entire of ... Corporation, plc ("Elan") (the "Original Offer").  On ...
Breaking Medicine Technology:China Biologic Comments on the Proposed Shanghai RAAS Transaction 2China Biologic Comments on the Proposed Shanghai RAAS Transaction 3China Biologic Comments on the Proposed Shanghai RAAS Transaction 4Auxilium Pharmaceuticals, Inc. To Present At The Deutsche Bank Health Care Conference 2Auxilium Pharmaceuticals, Inc. To Present At The Deutsche Bank Health Care Conference 3Auxilium Pharmaceuticals, Inc. To Present At The Deutsche Bank Health Care Conference 4Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 2Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 3Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 4Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 5Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 6Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 7Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 8Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 9
... InfoLogix, Inc. (Pink Sheets: IFLG ), ... the healthcare and commercial industries, announced today that it ... Faire and Regional Conference, sponsored by HIMSS South Florida ... Grand Hotel in Davies, FL (situated North of Miami) ...
... Mass., Oct. 25 GENFIT (Alternext: ALGFT; ISIN: FR0004163111), ... and development, focusing on the early diagnosis and preventive ... it has been selected by Windhover as one of ... the cardiovascular/metabolic category. This announcement is part of the ...
Cached Medicine Technology:InfoLogix to Present at South Florida Healthcare Trade Faire & Regional Conference 2GENFIT Selected by Windhover for the 2011 'Top Biopharma Projects To Watch' 2GENFIT Selected by Windhover for the 2011 'Top Biopharma Projects To Watch' 3
(Date:5/23/2013)... PHILADELPHIA, May 24, 2013 -- High blood glucose is ... of intensive insulin therapy (IIT) to control hyperglycemia is ... does not show a consistent benefit and even shows ... the American College of Physicians, (ACP) Clinical Guidelines Committee ... the American Journal of Medical Quality . , ...
(Date:5/23/2013)... Littleton, CO (PRWEB) May 23, 2013 ... environment, Special Operations Forces and law enforcement need an ... Night Vision Security Enhancer, Night VISER , is ... illuminator and motion sensing system to increase border and ... for Night VISER have more than tripled over the ...
(Date:5/23/2013)... May 24, 2013 In his pulse-quickening novel, ... the question, “Do you trust your government?” , In the ... killed en route to London ’s Heathrow Airport. His ... is left waiting for him to arrive at his ... death surfaces, Alan has doubts about the government’s report. When ...
(Date:5/23/2013)... Orange County film studio and visual effects ... light leaks for Apple's Final Cut Pro X today. ... no longer have to worry about matching up the movement ... Said Christina Austin, CEO of Pixel Film Studios, "You have ... look." , ProLeak from Pixel Film Studios allows users to ...
(Date:5/23/2013)... Branford, CT (PRWEB) May 23, 2013 ... patient satisfaction and perception management tools, and ASCA, ... to develop the new ASCA Benchmarking Program. ... in surveying technology and national benchmarking experience to ... with a comprehensive, state-of-the-art benchmarking tool. , “Voyance ...
Breaking Medicine News(10 mins):Health News:ACP issues recommendations for management of high blood glucose in hospitalized patients 2Health News:Lighting Up the Night: ARA Announces Record Sales of Its Night VISER System 2Health News:Lighting Up the Night: ARA Announces Record Sales of Its Night VISER System 3Health News:New Book “The AIDS Covenant” by Roy Harris Delivers Intriguing, Captivating Story 2Health News:Pixel Film Studios Releases ProLeak Light Leaks for Final Cut Pro X Today 2Health News:Voyance and ASCA Announce Strategic Partnership to Better the ASC Industry 2Health News:Voyance and ASCA Announce Strategic Partnership to Better the ASC Industry 3
... Researchers at Cambridge University in the UK have discovered ... play a significant role in triggering breast cancer in ... new methods of targeting younger women at higher-than-average risk ... with mammography before they reach 50 - the age ...
... of 'monkey see, monkey do.' Researchers at Ohio University ... red, they began to develop red and orange skin and ... such as macaques and leaf monkeys, all have trichromatic vision, ... red colors. Primatologists have disagreed about whether this type of ...
... a say in how they quit are more likely to ... new research at the University of Rochester . ... the University of Rochester School of Medicine and Dentistry, will ... demonstrate patient involvement in a quit plan leads to smokers ...
... an enzyme called Cdk5 in their brains by using the ... adept at learning and quicker at figuring out the changes ... ,"Its pretty rare that you make mice smarter, so ... senior study author Dr. James Bibb, Assistant Professor of Psychiatry, ...
... Published today in the American Diabetes Association journal Diabetes ... that the care of elderly patients with type 1insulin ... facilities fails to meet ADA Standards of Care. ... Intensity of Care?, a study authored Jay Shubrook, D.O., ...
... are the bad guys that help bacterial pathogens do their ... system. In essence, they knock down the front door of ... ,Now, researchers at the University of California, San Diego (UCSD) ... an effector protein called YpkA, one of several effectors of ...
Cached Medicine News:Health News:UK Scientists Identify Gene Mutations That Trigger Breast Cancer 2Health News:UK Scientists Identify Gene Mutations That Trigger Breast Cancer 3Health News:Color Vision Drove Primates to Develop Red Skin and Hair, Study Finds 2Health News:Choice is a Key Element in Success for Smokers Who Want to Quit 2Health News:Scientist Found New Mechanism for Brain Learning 2Health News:Diabetics in Nursing Homes Need Improved Care 2Health News:Diabetics in Nursing Homes Need Improved Care 3Health News:How Plague-Causing Bacteria Disarm Host Defense 2
... designed specifically for posteror ... injection of silicone oil ... Special high pressure tubing ... cannula. May also be ...
Product designed specifically for posteror segment surgical procedures. Facilitates posterior segment infusion. Flexible tubing 10in (25cm)....
For surgical treatment, repair and irrigation of the nasolacrimal system. Stainless steel probes, 23G x4 1/2in (.60mm x 11cm) Silicone tubing, length 14in (35cm), ID: .012in (.30mm) OD: .025in (.60mm...
...
Medicine Products: